324 related articles for article (PubMed ID: 19218281)
1. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas.
Soon PS; Gill AJ; Benn DE; Clarkson A; Robinson BG; McDonald KL; Sidhu SB
Endocr Relat Cancer; 2009 Jun; 16(2):573-83. PubMed ID: 19218281
[TBL] [Abstract][Full Text] [Related]
2. Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas.
Creemers SG; van Koetsveld PM; van Kemenade FJ; Papathomas TG; Franssen GJ; Dogan F; Eekhoff EM; van der Valk P; de Herder WW; Janssen JA; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2016 Sep; 23(9):727-37. PubMed ID: 27535174
[TBL] [Abstract][Full Text] [Related]
3. Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors.
Kiiveri S; Liu J; Arola J; Heikkilä P; Kuulasmaa T; Lehtonen E; Voutilainen R; Heikinheimo M
Mol Cell Endocrinol; 2005 Apr; 233(1-2):47-56. PubMed ID: 15767045
[TBL] [Abstract][Full Text] [Related]
4. Molecular markers and the pathogenesis of adrenocortical cancer.
Soon PS; McDonald KL; Robinson BG; Sidhu SB
Oncologist; 2008 May; 13(5):548-61. PubMed ID: 18515740
[TBL] [Abstract][Full Text] [Related]
5. DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions.
Blanes A; Diaz-Cano SJ
Hum Pathol; 2006 Oct; 37(10):1295-303. PubMed ID: 16949934
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors.
Soon PS; Libe R; Benn DE; Gill A; Shaw J; Sywak MS; Groussin L; Bertagna X; Gicquel C; Bertherat J; McDonald KL; Sidhu SB; Robinson BG
Ann Surg; 2008 Jan; 247(1):157-64. PubMed ID: 18156936
[TBL] [Abstract][Full Text] [Related]
7. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy.
Velázquez-Fernández D; Laurell C; Geli J; Höög A; Odeberg J; Kjellman M; Lundeberg J; Hamberger B; Nilsson P; Bäckdahl M
Surgery; 2005 Dec; 138(6):1087-94. PubMed ID: 16360395
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical evaluation of metallothionein, Mcm-2 and Ki-67 antigen expression in tumors of the adrenal cortex.
Szajerka A; Dziegiel P; Szajerka T; Zabel M; Winowski J; Grzebieniak Z
Anticancer Res; 2008; 28(5B):2959-65. PubMed ID: 19031940
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors.
De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456
[TBL] [Abstract][Full Text] [Related]
10. The molecular basis of adrenocortical cancer.
Lehmann T; Wrzesinski T
Cancer Genet; 2012 Apr; 205(4):131-7. PubMed ID: 22559973
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of childhood adrenocortical tumors.
West AN; Neale GA; Pounds S; Figueredo BC; Rodriguez Galindo C; Pianovski MA; Oliveira Filho AG; Malkin D; Lalli E; Ribeiro R; Zambetti GP
Cancer Res; 2007 Jan; 67(2):600-8. PubMed ID: 17234769
[TBL] [Abstract][Full Text] [Related]
12. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis.
Tömböl Z; Szabó PM; Molnár V; Wiener Z; Tölgyesi G; Horányi J; Riesz P; Reismann P; Patócs A; Likó I; Gaillard RC; Falus A; Rácz K; Igaz P
Endocr Relat Cancer; 2009 Sep; 16(3):895-906. PubMed ID: 19546168
[TBL] [Abstract][Full Text] [Related]
13. Nestin as a marker in the classification of adrenocortical tumors.
Lachenmayer A; Lichtenauer UD; Cox T; Schott M; Malendowicz LK; Goretzki PE; Cupisti K; Scherbaum WA; Bornstein SR; Willenberg HS
Horm Metab Res; 2009 May; 41(5):397-401. PubMed ID: 19294612
[TBL] [Abstract][Full Text] [Related]
14. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers.
Wang C; Sun Y; Wu H; Zhao D; Chen J
Histopathology; 2014 Mar; 64(4):567-76. PubMed ID: 24102952
[TBL] [Abstract][Full Text] [Related]
15. Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease.
de Cremoux P; Rosenberg D; Goussard J; Brémont-Weil C; Tissier F; Tran-Perennou C; Groussin L; Bertagna X; Bertherat J; Raffin-Sanson ML
Endocr Relat Cancer; 2008 Jun; 15(2):465-74. PubMed ID: 18508999
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic assessments of adrenocortical carcinomas by pathological features, immunohistochemical markers and reticular histochemistry staining.
Gan W; Han X; Gong Y; Yang Y; Wang C; Zhang Z
Diagn Pathol; 2024 May; 19(1):71. PubMed ID: 38802933
[TBL] [Abstract][Full Text] [Related]
17. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours.
Schmitt A; Saremaslani P; Schmid S; Rousson V; Montani M; Schmid DM; Heitz PU; Komminoth P; Perren A
Histopathology; 2006 Sep; 49(3):298-307. PubMed ID: 16918977
[TBL] [Abstract][Full Text] [Related]
18. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
[TBL] [Abstract][Full Text] [Related]
19. The glucocorticoid receptor is overexpressed in malignant adrenocortical tumors.
Tacon LJ; Soon PS; Gill AJ; Chou AS; Clarkson A; Botling J; Stalberg PL; Skogseid BM; Robinson BG; Sidhu SB; Clifton-Bligh RJ
J Clin Endocrinol Metab; 2009 Nov; 94(11):4591-9. PubMed ID: 19820023
[TBL] [Abstract][Full Text] [Related]
20. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms.
Nakazumi H; Sasano H; Iino K; Ohashi Y; Orikasa S
Mod Pathol; 1998 Dec; 11(12):1165-70. PubMed ID: 9872646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
